5 Science Park
395 Winchester Avenue
New Haven, CT 06511
United States
203 535 1456
https://www.arvinas.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 445
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. John G. Houston Ph.D. | Chairperson, CEO & President | 1.14M | N/A | 1960 |
Dr. Ian Taylor Ph.D. | Chief Scientific Officer | 732.26k | N/A | 1963 |
Mr. David K. Loomis M.B.A. | VP & Chief Accounting Officer | N/A | N/A | 1974 |
Mr. Jeff Boyle | Vice President of Investor Relations | N/A | N/A | N/A |
Mr. Jared M. Freedberg J.D. | General Counsel & Corporate Secretary | N/A | N/A | 1969 |
Mr. Steve Weiss | Senior VP & Chief Human Resources Officer | N/A | N/A | 1970 |
Dr. John A. Grosso Ph.D. | Senior Vice President of R&D Technical Operations | N/A | N/A | 1957 |
Dr. Randy Teel Ph.D. | Chief Business Officer | N/A | N/A | 1980 |
Ms. Angela M. Cacace Ph.D. | Senior Vice President of Neuroscience & Platform Biology | N/A | N/A | 1968 |
Mr. John P. Northcott | Chief Commercial Officer | N/A | N/A | 1978 |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Arvinas, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 2; Board: 8; Shareholder rights: 9; Compensation: 8.